---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024547"
form_type: "8-K"
ticker: "JUNS"
cik: "0001679628"
company_name: "JUPITER NEUROSCIENCES, INC."
filed_at: "2026-05-20T13:45:15+00:00"
generated_at: "2026-05-20T13:47:11.909140+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA

## Summary
- Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
- Development milestones: $3.33M upon Phase 3 initiation and $20M on FDA approval.
- Commercialization milestones up to $93.33M at net sales thresholds of $333M, $1B, $2B; plus perpetual 3% royalty.
- 90-day exclusivity period; definitive agreement target within 90 days; reverse termination fee of $600K if not executed.
- Deal follows President Trump's April 18, 2026 Executive Order on psychedelic medicine; ALA-002 is an FDA-designated NCE.

## SEC filing metadata
- accession: 0001493152-26-024547
- form_type: 8-K
- ticker: JUNS
- cik: 0001679628
- company_name: JUPITER NEUROSCIENCES, INC.
- filed_at: 2026-05-20T13:45:15+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1679628/000149315226024547/0001493152-26-024547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1679628/000149315226024547/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024547
- JSON: https://secwatch.observer/filing/0001493152-26-024547.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.